Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. alleging securities fraud affecting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical Concepts, Inc. made false statements regarding the impact of competition on the demand for its primary product, the 3D bunion correction system, "Lapiplasty" [2]. - It is alleged that due to competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2]. - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Treace Medical Concepts, Inc. (NASDAQ: TMCI) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Allegations include that competition negatively impacted the demand for the Lapiplasty system, leading to a decline in Treace Medical's revenue [3]. - The company needed to accelerate plans for an alternative product to osteotomy due to these challenges [3]. - Defendants' positive statements about the company's business and prospects were claimed to be materially misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by June 10, 2025, to participate in potential recovery [4]. - Registration will include enrollment in a portfolio monitoring software for status updates throughout the case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Treace Medical Concepts concealed the impact of competition on the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [2] - As a result of competitive pressures, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2] - Defendants allegedly made materially misleading positive statements regarding the company's business, operations, and future prospects [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] Financial Performance - Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to a range of $201 million to $211 million [3] - Following this announcement, Treace Medical's stock price fell by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Group 1: Allegations and Impact - The lawsuit claims that competition negatively affected the demand and utilization of the Lapiplasty system [3]. - As a result of the competitive pressure, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [3]. - The defendants' positive statements about the company's business and prospects were allegedly misleading and lacked a reasonable basis [3]. Group 2: Class Action Details - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Shareholders who purchased TMCI shares during this period are encouraged to register for the class action, with a deadline set for June 10, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the class period from May 8, 2023, to May 7, 2024 [1] Group 1: Allegations and Impact - The complaint alleges that competition negatively affected the demand and utilization of Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty" [1] - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1] - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - Shareholders who purchased shares of TMCI during the specified class period are encouraged to register for the class action, with a deadline of June 10, 2025, to seek lead plaintiff status [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2] - Participation in the case incurs no cost or obligation for the shareholders [2] Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc for alleged securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves Treace Medical and certain officers and/or directors accused of engaging in securities fraud [2]. - Investors who purchased Treace Medical securities during the Class Period have until June 10, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million [3]. - The company cited competition from minimally invasive osteotomy and Lapiplasty "knockoffs" as headwinds affecting Lapiplasty growth [3]. Group 3: Stock Market Reaction - Following the revenue guidance cut, Treace Medical's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4].

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI). Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=147738&from=3 ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information affecting the company's stock value [1]. Group 1: Allegations and Impact - The complaint alleges that during the class period from May 8, 2023, to May 7, 2024, Treace Medical faced competition that negatively impacted the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [1]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1]. - The defendants are accused of making materially misleading statements about the company's business operations and future prospects, lacking a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased TMCI shares during the specified class period are encouraged to register for the class action, with a deadline set for June 10, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. - Participation in the case does not incur any cost or obligation for the shareholders [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of the company's stock [3].

PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same pe ...